DLBCL

Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Dipenkumar Modi, MD, and participants discussed the leading later-line therapy options for patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable discussion, Mehdi H. Hamadani, MD, discussed systemic therapy options for relapsed/refractory diffuse large B-cell lymphoma.

Dr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.

An expert describes factors for consideration when choosing a second-line treatment for relapsed DLBCL.

Grzegorz S. Nowakowski, MD, reviews the approved further-line treatment options for relapsed DLBCL.

An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.

Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.

A discussion on the clinical factors that put patients at risk of having relapsed DLBCL.

Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Stephen Ansell, MD, PhD, discussed the options for third-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.

During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.

According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.

In the EPCORE NHL-2 trial , epcoritamab therapy was manageable and achieved high rates of response in patients with high-risk diffuse large B-cell lymphoma.

During a Targeted Oncology case-based event, Elizabeth Budde, MD, PhD, discussed with participants the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was not eligible for stem cell transplant and declined chimeric antigen receptor T-cell therapy.

Matthew J. Matasar, MD, discusses the current landscape of diffuse large B-cell lymphoma.

Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.

During a case-based roundtable event, Matthew McKinney, MD, discussed data supporting the use of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a live virtual event, Brian T. Hill, MD, discussed the results of the L-MIND study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse B-cell lymphoma.

During a live virtual event, Jason Westin, MD, discussed the challenges of giving patients access to chimeric antigen receptor T-cell therapy.

During a Targeted Oncology case-based roundtable event, Victor Yazbeck, MD, MS, discussed the data from recent clinical trials of tafasitamab/lenalidomide, polatuzumab vedotin, and loncastuximab tesirine for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, John M. Burke, MD, discussed decision-making for third-line therapy for an elderly patient with diffuse large B-cell lymphoma.

Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.

Tafasitamab-cxi plus lenalidomide has been added to the NCCN Guidelines as a preferred regimen for patients with diffuse large B-cell lymphoma.

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the outcomes of clinical trials of tafasitamab plus lenalidomide as well as loncastuximab tesirine in diffuse large B-cell lymphoma.